0
0

To direct the Director of the National Institutes of Health and the Secretary of Health and Human Services to evaluate hormone variability and hormone testing, respectively, in women with respect to perimenopause.

5/30/2026, 8:06 AM

Summary of Bill HR 9077

The bill "To direct the Director of the National Institutes of Health and the Secretary of Health and Human Services to evaluate hormone variability and hormone testing, respectively, in women with respect to perimenopause" was introduced in the 119th session of Congress as H.R. 9077 on May 29, 2026. The bill aims to instruct the Director of NIH and the Secretary of HHS to assess hormone variability and testing specifically in women during the perimenopausal period.

Current Status of Bill HR 9077

Bill HR 9077 is currently in the status of Bill Introduced since May 29, 2026. Bill HR 9077 was introduced during Congress 119 and was introduced to the House on May 29, 2026.  Bill HR 9077's most recent activity was Referred to the House Committee on Energy and Commerce. as of May 29, 2026

Bipartisan Support of Bill HR 9077

Total Number of Sponsors
1
Democrat Sponsors
1
Republican Sponsors
0
Unaffiliated Sponsors
0
Total Number of Cosponsors
0
Democrat Cosponsors
0
Republican Cosponsors
0
Unaffiliated Cosponsors
0

Policy Area and Potential Impact of Bill HR 9077

Primary Policy Focus

Alternate Title(s) of Bill HR 9077

To direct the Director of the National Institutes of Health and the Secretary of Health and Human Services to evaluate hormone variability and hormone testing, respectively, in women with respect to perimenopause.
To direct the Director of the National Institutes of Health and the Secretary of Health and Human Services to evaluate hormone variability and hormone testing, respectively, in women with respect to perimenopause.

Comments